For Immediate Release
Chicago, IL – September 12, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Teleflex Incorporated (TFX - Free Report) , Apple Inc. (AAPL - Free Report) , Covidien , C.R. Bard and CareFusion .
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: https://at.zacks.com/?id=5513
Here are highlights from Tuesday’s Analyst Blog:
Teleflex Takes Up Online Marketing
Recently, Teleflex Incorporated (TFX - Free Report) , a global leader in medical devices used in critical care and surgery, launched its latest online catalog for Hudson RCI Respiratory products. The intuitive catalog is available on the company website.
Through its Teleflex Medical division, the company develops and provides various brands of products such as Hudson RCI, Rusch and Arrow among others. Teleflex is marketing its respiratory and anesthesia products under the Hudson RCI brand since July, 2004.
The Hudson RCI brand provides a wide portfolio which includes oxygen therapy products, aerosol therapy products, passive humidification and filtration products, active humidification and breathing circuits, resuscitation bags, incentive spirometers and adaptors and connectors. The online catalog encompassing these products is compatible with traditional desktops as well as other high-end smartphones, gadgets and tablets including Apple Inc.’s (AAPL - Free Report) iPad.
According to Teleflex, the online catalog will provide a convenient, 24 hour access to the consumers. It is also expected to build customer relationships as the web provides an interactive medium to the company.
Not only the online catalogs are more flexible and inexpensive, they also offer a wider access to customers as the internet connects millions of global citizens. It will also allow Teleflex to easily and frequently update product and price information for prospective customers.
Aided by this online marketing initiative, Limerick, Pennsylvania-based Teleflex might be able to gain an edge over its competitors and bolster its top line. The company’s strategy to develop new, innovative products along with the divestiture of its OEM Orthopedic division should help improve its financial performance in the long run. The company’s focus on profitable and consistent growth along with the introduction of new products as well as portfolio expansion via acquisitions is expected to yield results.
However, Covidien , C.R. Bard and CareFusion , which operate in similar business segments, present a tough competitive landscape for Teleflex. Additionally, the company operates in a stringent regulatory environment. The demand for its products is susceptible to healthcare reimbursement systems in the domestic as well as the international market.
Teleflex currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: https://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: https://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at https://at.zacks.com/?id=5518.
Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339